Welcome Carl Stubbings: InGeNA’s New Chair

InGeNA is delighted to announce the appointment of Carl Stubbings as our new Chair. With an exceptional career spanning leadership roles in biotechnology and genomics, Carl brings extensive strategic insight to our organisation.

Recently stepping down from his role as Chief Commercial Officer at Genetic Technologies, Carl’s commitment to InGeNA’s mission led him to apply for the Independent Chair position. His passion for advancing the genomics industry and driving transformative healthcare solutions made him the ideal candidate for this critical leadership role.

A seasoned Executive and Non-Executive Director with extensive experience across multiple ASX-listed companies, Carl has consistently demonstrated a deep commitment to healthcare innovation. His professional journey includes roles with organisations such as Sanguibio, BARD1 Life Sciences, and Sienna Cancer Diagnostics.

Carl is a passionate advocate for transforming healthcare from a reactive “sick care” model to a proactive, personalised approach. He believes genomics offers an unprecedented opportunity to understand individual health at a molecular level, enabling more precise and effective healthcare interventions.

“I am committed to working hard to deliver on the great opportunity for InGeNA,” Carl stated. “Our mission is to drive the adoption of genomics and personalised medicine, moving beyond one-size-fits-all treatments to truly individualised healthcare.”

As a member-elected Director with a track record of strategic leadership, Carl understands the critical importance of collaboration and industry alignment. His vision for InGeNA aligns perfectly with our goal of bringing a unified industry perspective to the rapidly evolving genomics landscape.

We are excited to welcome Carl and look forward to the innovative leadership he will bring to InGeNA.